The current work was aimed at elucidating the role and the impact of APE1 in the onset of inflammatory circuits in liver diseases, such as those associated to NASH and to evaluate whether the APE1 redox inhibitor, i.e. E3330, may prevent the induction of IL-8 and IL-6 expression by both TNF-α or FA treatment. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.